Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Biomarin Pharmaceutical, maintaining a price target of $110.
September 09, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Biomarin Pharmaceutical, maintaining a price target of $110, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $110 by Cantor Fitzgerald suggests a positive outlook for Biomarin Pharmaceutical. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100